Coherus Oncology (CHRS) Shares Outstanding (Weighted Average) (2012 - 2026)

Coherus Oncology has disclosed Shares Outstanding (Weighted Average) across 15 years of filings, most recently posting $136.4 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $136.4 million, up 17.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $136.4 million (up 17.73% YoY), and the FY2025 annual result was $117.1 million, up 2.26% from the prior year.
• Shares Outstanding (Weighted Average) came in at $136.4 million for Q1 2026 at Coherus Oncology, up from $117.1 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $136.4 million in Q1 2026 to a low of $77.3 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $112.7 million (2024), against an average of $101.0 million.
• Across the five-year window, Shares Outstanding (Weighted Average) surged 42.24% in 2024 and gained 1.0% in 2025, its largest moves.
• Coherus Oncology's Shares Outstanding (Weighted Average) stood at $77.6 million in 2022, then increased by 21.3% to $94.2 million in 2023, then advanced by 21.65% to $114.6 million in 2024, then gained by 2.26% to $117.1 million in 2025, then grew by 16.44% to $136.4 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $136.4 million (Q1 2026), $117.1 million (Q4 2025), and $116.2 million (Q3 2025), per Business Quant data.